These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1506622)

  • 1. A marked molecular heterogeneity of growth hormone (GH) detected in the plasma but not pituitary of a patient with acromegaly: comparison with other acromegalics and an implication for discrepant plasma levels of GH and insulin-like growth factor.
    Watanobe H; Ishii M; Kudo T; Nagata A; Takebe K
    J Endocrinol Invest; 1992 May; 15(5):381-6. PubMed ID: 1506622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
    Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
    Ezzat S; Kontogeorgos G; Redelmeier DA; Horvath E; Harris AG; Kovacs K
    Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
    Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
    PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size heterogeneity of circulating growth hormone in acromegaly. "Big-big" GH forms are associated with inappropriately low IGF-I levels.
    Arosio M; Nissim M; Ballabio M; Orefice R; Bazzoni N; Faglia G
    Acta Endocrinol (Copenh); 1991 Aug; 125(2):150-9. PubMed ID: 1897332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone releasing hormone-sensitive adenylate cyclase activity in growth hormone-producing pituitary adenoma: correlation to the response of plasma growth hormone to growth hormone releasing hormone in patients with acromegaly.
    Natori S; Ikuyama S; Haji M; Ohashi M; Nawata H
    Endocrinol Jpn; 1989 Apr; 36(2):229-36. PubMed ID: 2550207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation.
    Pagesy P; Li JY; Rentier-Delrue F; Delalande O; Le Bouc Y; Kujas M; Joubert D; Martial J; Peillon F
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):745-52. PubMed ID: 1695808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inappropriately low serum GH in an acromegalic: lysosomal involvement in intracellular hormone degradation.
    Mashiter K; De Marco L; Van Noorden S; Adams E; Loizou M; Joplin GF; Peters TJ
    Metabolism; 1982 Sep; 31(9):931-6. PubMed ID: 7121264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M; Günther T; von zur Mühlen A; Brabant G
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphofunctional study of pituitary adenomas with acromegaly by immunoperoxidase technique and electron microscopy.
    Fukaya T; Kageyama N; Kuwayama A; Takanohashi M; Okada C; Yoshida J; Osamura Y
    Cancer; 1980 Apr; 45(7):1598-1603. PubMed ID: 6989477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
    Schwyzer L; Starke RM; Jane JA; Oldfield EH
    J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia.
    Lim DJ; Kwon HS; Cho JH; Kim SH; Choi YH; Yoon KH; Cha BY; Lee KW; Son HY; Kang SK
    Endocr J; 2007 Aug; 54(4):537-41. PubMed ID: 17575366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of immunostaining for growth hormone in a subset of patients with acromegaly.
    Schroeder JL; Spiotta AM; Fleseriu M; Prayson RA; Hamrahian AH; Weil RJ
    Pituitary; 2014 Apr; 17(2):103-8. PubMed ID: 23475513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
    Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative differences between immunological and receptor binding activities of hGH in pituitary adenomas from patients with acromegaly.
    Hizuka N; Takano K; Shizume K; Asakawa K; Miyakawa M
    Endocrinol Jpn; 1984 Dec; 31(6):719-24. PubMed ID: 6099801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ; Harris AG; Lamberts SW
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell.
    Beck-Peccoz P; Bassetti M; Spada A; Medri G; Arosio M; Giannattasio G; Faglia G
    J Clin Endocrinol Metab; 1985 Sep; 61(3):541-6. PubMed ID: 2410443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors.
    Ishibashi M; Yamaji T; Takaku F; Teramoto A; Fukushima T
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1187-93. PubMed ID: 2437140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a circulating growth hormone stimulating factor other than growth hormone releasing hormone in a patient with pituitary tumour and acromegaly.
    Hulting AL; Wersäll J; Werner S
    Acta Endocrinol (Copenh); 1985 Jul; 109(3):289-94. PubMed ID: 3927648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
    Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.